Cited by 93Advanced Glycation End Products researchImmune Response and InflammationInflammation biomarkers and pathways

The role of RAGE in host pathology and crosstalk between RAGE and TLR4 in innate immune signal transduction pathways

Open access
Prantner, Daniel, Nallar, Shreeram, Vogel, Stefanie N.·2020·The FASEB Journal

Abstract

Although the innate immune receptor protein, Receptor for Advanced Glycation End products (RAGE), has been extensively studied, there has been renewed interest in RAGE for its potential role in sepsis, along with a host of other inflammatory diseases of chronic, noninfectious origin. In contrast to other innate immune receptors, for example, Toll‐like receptors (TLRs), that recognize ligands derived from pathogenic organisms that are collectively known as “pathogen‐associated molecular patterns” (PAMPs) or host‐derived “damage‐associated molecular patterns” (DAMPs), RAGE has been shown to recognize a broad collection of DAMPs exclusively. Historically, these DAMPs have been shown to be pro‐inflammatory in nature. Early studies indicated that the adaptor molecule, MyD88, might be important for this change. More recent studies have explored further the mechanisms underlying this inflammatory change. Overall, the newer results have shown that there is extensive crosstalk between RAGE and TLRs. The three canonical RAGE ligands, Advanced Glycation End products (AGEs), HMGB1, and S100 proteins, have all been shown to activate both TLRs and RAGE to varying degrees in order to induce inflammation in in vitro models. As with any field that delves deeply into innate signaling, obstacles of reagent purity may be a cause of some of the discrepancies in the literature, and we have found that commercial antibodies that have been widely used exhibit a high degree of nonspecificity. Nonetheless, the weight of published evidence has led us to speculate that RAGE may be physically interacting with TLRs on the cell surface to elicit inflammation via MyD88‐dependent signaling.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1096/fj.202002136r

Cites

161 of 161 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Prantner, D., Nallar, S., & Vogel, S. N.
Affiliations
University of Maryland, Baltimore (US)
Corresponding author
Vogel, Stefanie N.
Venue
The FASEB Journal
Publisher
Wiley
Published
2020-11
Volume
34
Issue
12
Pages
15659-15674
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W3096351980
Cited by
92
References
160
Citations by year
2026: 14 · 2025: 12 · 2024: 16 · 2023: 22 · 2022: 11 · 2021: 16
FWCI
1.57
Type
journal article
Language
en
Open access
Locations
  • The FASEB Journal (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health (AI123371, AI125215, S10 OD025101)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Keywords
receptor for advanced glycation end products, RAGE, TLR4, innate immune signaling, damage-associated molecular patterns, advanced glycation end products, HMGB1, S-100 protein, MyD88, receptor cross-talk, sepsis, inflammation
MeSH terms
Receptor for Advanced Glycation End Products, Animals, Humans, Immunity, Innate, Inflammation, Signal Transduction, Toll-Like Receptor 4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review